Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mohamed El Geneidy (NPI 1447474978)

Field	Value
Entity Type	Individual
Organization	Mohamed El Geneidy
Address	166 Stoneridge Drive
City	Columbia
State	SC
ZIP	29210
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 13, 2007

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

MOHAMED EL GENEIDY is a Hematology & Oncology Physician with a long Medicare billing history, enumerated since 2007-04-13 (~19 years ago). That tenure indicates established practice patterns and sustained participation in Medicare over nearly two decades, supporting experience with oncology infusion workflows and chronic cancer care management in the Columbia, SC market.

This provider’s lifetime Medicare revenue totals $2.1M and there is no Medicaid billing on file, making their practice effectively single-payer (Medicare) in the available data. The absence of Medicaid activity suggests limited engagement with Medicaid populations or services not captured in Medicaid claims, which has implications for payer mix, contract negotiation focus, and downstream revenue risk concentration.

Revenue concentration is high: the precomputed top 3 Medicare codes account for 62.0% of this provider’s total Medicare revenue. The largest single-code driver is J9271 (pembrolizumab) at $851.4K (42.5% of Medicare revenue), followed by J0897 (denosumab) at $235.4K (11.7%) and 99214 office visits at $154.8K (7.7%); this mix indicates that high-cost oncology drug administration and associated evaluation-and-management visits dominate revenue.

The code mix and top revenue lines point to an infusion-focused oncology practice model: J9271 (pembrolizumab) and J0897 (denosumab) are injectable oncology/adjunct agents and together with chemotherapy administration CPTs (96413, 96365) and multiple supportive drug J-codes, the practice appears to deliver in-office biologic and chemotherapy infusions rather than primarily surgical or radiation oncology services.

Competitive standing by code is mixed: for J9271 the provider ranks #406 of 1841 nationally (77th percentile), which is a solid but not leading position—consistent with being a typical, unremarkable volume provider for pembrolizumab at the national level. For J0897 the provider ranks #701 of 10057 (93rd percentile), indicating comparatively higher national relative volume for denosumab, while 99214 ranks #2425 of 479517 (99th percentile) and is labeled an extreme outlier, meaning this provider bills an unusually large volume of mid-level established-patient E/M visits relative to national peers.

Several supporting codes show notably high relative volumes that reinforce an infusion clinic profile: J1627 (granisetron extended-release) and J0185 (aprepitant) have large claim counts and rank in upper percentiles, and codes such as 96361 (additional IV fluids) rank #28 of 2548 providers (99th percentile), described as notably above typical national volume—together these indicate sustained supportive-care and infusion throughput.

Procedure-level lab and diagnostic services are also prominent in the revenue mix: multiple laboratory panels (80048, 80076, 85025) each contribute roughly $20K and rank in very high national percentiles (mostly 98th), suggesting in-office or closely affiliated lab utilization, while imaging-related codes (78815 PET/CT and A9552 FDG) contribute additional specialized diagnostic revenue.

Although many individual drug codes have typical, unremarkable national volumes, the provider shows concentrated dependence on a small number of high-revenue biologics and a high volume of established-patient E/M visits. This concentration implies revenue risk if utilization or reimbursement for those top agents or E/M coding patterns change, and it also highlights the provider’s potential leverage in payer negotiations focused on oncology drug reimbursement and infusion services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

73 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	19,800	$40	$851.4K
J0897	Injection, denosumab, 1 mg	13,080	$20	$235.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,700	$90	$154.8K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	4,360	$30	$113.3K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	950	$90	$88.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,430	$40	$87.5K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	100	$710	$73.4K
J1627	Injection, granisetron, extended-release, 0.1 mg	12,400	$10	$62K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	470	$100	$44.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	360	$80	$30.2K

Showing 1–10 of 73

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 73 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Mohamed El Geneidy — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

73 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	15	30	19,700	$40	$832K
J1569	13	20	3,860	$40	$161.4K
J1449	5	10	4,090	$30	$98.8K
J0897	28	250	2,400	$20	$91.2K
J3490	28	50	70	$510	$57.7K
J2506	9	10	740	$80	$55.9K
Q5122	2	10	540	$90	$55.6K
J1627	3	10	10,400	$1	$46.3K
J1439	23	30	42,750	$1	$42.3K
J0881	7	10	19,760	$1	$42.3K

Showing 1–10 of 73

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mohamed El Geneidy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Riverside Radiology And Interventional Associates Inc	OH	Diagnostic Radiology Physician	$0	$30.3M
Somc Medical Care Foundation, Inc.	OH	Family Medicine Physician	$0	$25.3M
Musc Community Physicians	SC	Internal Medicine Physician	$0	$16.7M
Kershaw Hospital LLC	SC	General Acute Care Hospital	$0	$8M
Musc Community Physicians	SC	Family Medicine Physician	$0	$5.6M
Charles Butler	SC	Internal Medicine Physician	$3.8M	$0
Lindsay Gamble	SC	Family Nurse Practitioner	$3.7M	$0
Aaron Flanders	FL	Hematology & Oncology Physician	$3.5M	$0
Jill Sullivan	SC	Internal Medicine Physician	$3.4M	$0
Robert Collins	SC	Internal Medicine Physician	$2.7M	$0

Nearby Providers

Other providers in the same ZIP code as Mohamed El Geneidy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
South Carolina Youth Advocate Program	SC	Community/Behavioral Health Agency	$0	$64M
Lifehme, Inc.	SC	Oxygen Equipment & Supplies (DME)	$0	$45.6M
Pal-med, LLC	SC	Durable Medical Equipment & Medical Supplies	$0	$26.2M
Bright Start, LLC	SC	Speech-Language Pathologist	$0	$20.8M
Kids First Dental, LLC	SC	Dentist	$0	$20.6M
Hospice Care Of South Carolina, Lowcountry, LLC	SC	Community Based Hospice Care Agency	$0	$19.9M
Crescent Hospice, Inc.	SC	Community Based Hospice Care Agency	$0	$17.3M
Coram Healthcare/carolina Home Therapeutics	SC	Home Infusion Therapy Pharmacy	$0	$13.9M
Caring Healthcare, Inc.	SC	Nursing Care Agency	$0	$13.3M
Richland/lexington Disabilities And Special Needs Board	SC	Case Management Agency	$0	$11.3M

Mohamed El Geneidy — Billing Profile & Reimbursement Data

Sign up for Mohamed El Geneidy — Billing Profile & Reimbursement Data policy alerts

Mohamed El Geneidy — Billing Profile & Reimbursement Data

Sign up for Mohamed El Geneidy — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References